Background
Background People in a putatively late People in a putatively late prodromal state not only have an prodromal state not only have an enhanced risk for psychosis but already enhanced risk for psychosis but already suffer from mental and functional suffer from mental and functional disturbances. disturbances.
Aims Aims To evaluate the acute effects of a
To evaluate the acute effects of a combined supportive and antipsychotic combined supportive and antipsychotic treatment on prodromal symptoms. treatment on prodromal symptoms.
Method Method Putatively prodromal
Putatively prodromal individuals were randomly assigned to a individuals were randomly assigned to a needs-focused intervention without needs-focused intervention without ( (n n¼59) or with amisulpride ( 59) or with amisulpride (n n¼65). 65). Outcome measures at12-weeks effects Outcome measures at12-weeks effects were prodromal symptoms, global were prodromal symptoms, global functioning and extrapyramidal sidefunctioning and extrapyramidal sideeffects. effects.
Results
Results Amisulpride plus the needsAmisulpride plus the needsfocused intervention produced superior focused intervention produced superior effects on attenuated and full-blown effects on attenuated and full-blown psychotic symptoms, basic, depressive and psychotic symptoms, basic, depressive and negative symptoms, and global negative symptoms, and global functioning.Main side-effects were functioning.Main side-effects were prolactin associated. prolactin associated.
Conclusions Conclusions Coadministration of
Coadministration of amisulpride yielded a marked symptomatic amisulpride yielded a marked symptomatic benefit.Effects require confirmation by a benefit.Effects require confirmation by a placebo-controlled study. placebo-controlled study.
Declaration of interest Declaration of interest None.
None. Funding detailed in Acknowledgements. Funding detailed in Acknowledgements.
The onset of psychosis is mostly preceded The onset of psychosis is mostly preceded by a prodromal phase lasting about 5 years by a prodromal phase lasting about 5 years (Hafner (Hä fner et al et al, 1998) . This period is charac-, 1998). This period is characterised by various mental disturbances such terised by various mental disturbances such as negative and basic symptoms, attenuated as negative and basic symptoms, attenuated and brief transient frank psychotic sympand brief transient frank psychotic symptoms, cognitive impairments, and a marked toms, cognitive impairments, and a marked decline of social functioning and quality of decline of social functioning and quality of life (Hafner life (Hä fner et al et al, 1998; Klosterkotter , 1998; Klosterkö tter et al et al, , 2001; Bechdolf 2001; Bechdolf et al et al, 2005; Pukrop , 2005; Pukrop et al et al, , 2006; Yung 2006; Yung et al et al, 2006) . Hence, indepen-, 2006) . Hence, independently from its potential course into psydently from its potential course into psychosis, this syndrome itself already fulfils chosis, this syndrome itself already fulfils the criteria for a mental disorder as defined the criteria for a mental disorder as defined in DSM-IV (American Psychiatric Associain DSM-IV (American Psychiatric Association, 1994) . With no approved treatment tion, 1994). With no approved treatment existing to date, one major objective of existing to date, one major objective of the early intervention studies of the the early intervention studies of the German Research Network on SchizoGerman Research Network on Schizophrenia (GRNS) is the development of therphrenia (GRNS) is the development of therapeutic strategies related to the current apeutic strategies related to the current clinical state (Hafner clinical state (Häfner et al et al, 2004; Ruhrmann , 2004; Ruhrmann et al et al, 2005) . The present study aimed to , 2005) . The present study aimed to evaluate the short-term symptomatic effects evaluate the short-term symptomatic effects of a needs-focused intervention combined of a needs-focused intervention combined with amisulpride. with amisulpride.
METHOD METHOD Participants Participants
Participants were recruited at the early Participants were recruited at the early detection centres of the Departments of detection centres of the Departments of Psychiatry at the Universities of Cologne, Psychiatry at the Universities of Cologne, Bonn, Dusseldorf and Munich. They were Bonn, Dü sseldorf and Munich. They were mainly referred by psychiatrists or psychomainly referred by psychiatrists or psychological therapists in private practice, general logical therapists in private practice, general practitioners and school or university counpractitioners and school or university counselling services, or presented themselves selling services, or presented themselves directly. The concept of early detection was directly. The concept of early detection was introduced into the local health network by introduced into the local health network by numerous workshops and talks. To facilitate numerous workshops and talks. To facilitate risk screening, a 17-item checklist was disrisk screening, a 17-item checklist was distributed (Hafner tributed (Häfner et al et al, 2004) , which was , 2004) , which was drawn from the Early Recognition Inventory drawn from the Early Recognition Inventory (ERIraos; Maurer (ERIraos; Maurer et al et al, 2006) . , 2006). The study adhered to the Guideline for The study adhered to the Guideline for Good Clinical Practice CPMP/ICH/135/95 Good Clinical Practice CPMP/ICH/135/95 and CPMP/768/97 (ICH, 1996) , the and CPMP/768/97 (ICH, 1996) , the 1996 1996
World Medical Association Declaration World Medical Association Declaration of of Helsinki and pertinent German legal and Helsinki and pertinent German legal and regulatory requirements, and was approved regulatory requirements, and was approved by the local ethics committees of the medical by the local ethics committees of the medical faculties of the participating centres. All faculties of the participating centres. All participants gave their written informed participants gave their written informed consent and were explicitly informed that consent and were explicitly informed that they were free to withdraw from the study they were free to withdraw from the study at any time for any reason, without effect at any time for any reason, without effect on their medical care. No financial induceon their medical care. No financial inducement was offered for participation. ment was offered for participation.
Inclusion criteria Inclusion criteria
Within the GRNS, a two-phase model Within the GRNS, a two-phase model which differentiates between an early which differentiates between an early (EIPS) and a late initial prodromal state (EIPS) and a late initial prodromal state (LIPS) of psychosis is being evaluated. The (LIPS) of psychosis is being evaluated. The late prodromal state is defined by the preslate prodromal state is defined by the presence of attenuated positive symptoms and/ ence of attenuated positive symptoms and/ or brief limited intermittent positive sympor brief limited intermittent positive symptoms within the 3 months preceding the toms within the 3 months preceding the study. Attenuated positive symptoms study. Attenuated positive symptoms (APS) are defined by the presence of at least (APS) are defined by the presence of at least one of the following appearing several one of the following appearing several times per week for a period of at least 1 times per week for a period of at least 1 week: (a) ideas of reference; (b) odd beliefs week: (a) ideas of reference; (b) odd beliefs or magical thinking; (c) unusual perceptual or magical thinking; (c) unusual perceptual experiences; (d) odd thinking and speech; experiences; (d) odd thinking and speech; and/or (e) suspiciousness or paranoid ideaand/or (e) suspiciousness or paranoid ideation. Brief limited intermittent positive tion. Brief limited intermittent positive symptoms (BLIPS) comprise the presence symptoms (BLIPS) comprise the presence of hallucinations, delusions, formal thought of hallucinations, delusions, formal thought disorder, or gross disorganised or catatonic disorder, or gross disorganised or catatonic behaviour, spontaneously resolving within behaviour, spontaneously resolving within 1 week. APS and BLIPS were assessed by 1 week. APS and BLIPS were assessed by dedicated questions of the ERIraos (Maurer dedicated questions of the ERIraos (Maurer et al et al, 2006) . The age range of participants , 2006). The age range of participants was 18-36 years (younger people could was 18-36 years (younger people could not be included because all participating not be included because all participating centres were certified to treat adults only centres were certified to treat adults only and older people were considered to be at and older people were considered to be at low risk for psychosis). low risk for psychosis).
Exclusion criteria Exclusion criteria
The most relevant exclusion criteria were: The most relevant exclusion criteria were: (a) any lifetime DSM-IV diagnosis of (a) any lifetime DSM-IV diagnosis of schizophrenia, schizophreniform, schizoschizophrenia, schizophreniform, schizoaffective, delusional or bipolar disorder; affective, delusional or bipolar disorder; (b) any lifetime DSM-IV diagnosis of brief (b) any lifetime DSM-IV diagnosis of brief psychotic episode with a duration of more psychotic episode with a duration of more than 1 week; (c) a DSM-IV diagnosis of dethan 1 week; (c) a DSM-IV diagnosis of delirium, dementia, amnestic and other cognilirium, dementia, amnestic and other cognitive disorders, mental retardation, mental tive disorders, mental retardation, mental disorders due to a general medical condidisorders due to a general medical condition or mental disturbances due to psychotion or mental disturbances due to psychotropic substances; (d) abuse of alcohol or tropic substances; (d) abuse of alcohol or drugs within the past 3 months or the past drugs within the past 3 months or the past 4 weeks for cannabis (if prodromal symp-4 weeks for cannabis (if prodromal symptoms did not appear before any drug abuse, toms did not appear before any drug abuse, s 8 8 s 8 8 they had to persist after a period of at least they had to persist after a period of at least 3 months free of hallucinations or ampheta-3 months free of hallucinations or amphetamines lasting or after 4 weeks free of cannamines lasting or after 4 weeks free of cannabis.); (e) any lifetime continuous treatment bis.); (e) any lifetime continuous treatment with high-potency antipsychotics for more with high-potency antipsychotics for more than 1 week or any use of antipsychotics than 1 week or any use of antipsychotics during the 6 months prior to the study; (f) during the 6 months prior to the study; (f) any contraindication for amisulpride; (g) any contraindication for amisulpride; (g) women of childbearing risk not using women of childbearing risk not using contraception. contraception. Additional exclusion criteria Additional exclusion criteria were related to somatic disturbances such were related to somatic disturbances such as pathological electrocardiographic (ECG) as pathological electrocardiographic (ECG) aberrations etc. aberrations etc.
Measures Measures
The , 1992 ) and allows prospective follow-up 1992) and allows prospective follow-up studies. The psychopathological section studies. The psychopathological section comprises 110 items with scores ranging comprises 110 items with scores ranging from 0 to 3. Assessments were trained by from 0 to 3. Assessments were trained by the scale's authors, kappa for interrater the scale's authors, kappa for interrater reliability ranged between 0.55 and 0.69. reliability ranged between 0.55 and 0.69. To assess treatment effects, a Basic and PoTo assess treatment effects, a Basic and Positive Psychotic Spectrum Symptoms score sitive Psychotic Spectrum Symptoms score (ERI-BAPPSS score) was formed of the 16 (ERI-BAPPSS score) was formed of the 16 items related to full-blown psychotic sympitems related to full-blown psychotic symptoms (including disorganised thinking and toms (including disorganised thinking and behaviour), of the six items assessing attebehaviour), of the six items assessing attenuated positive symptoms described above nuated positive symptoms described above and of the ten items assessing a set of basic and of the ten items assessing a set of basic symptoms which have been shown to be symptoms which have been shown to be highly predictive for the development of highly predictive for the development of schizophrenia (Klosterkotter schizophrenia (Klosterkö tter et al et al, 2001) . , 2001). Two sub-scores of the ERI-BAPPSS score Two sub-scores of the ERI-BAPPSS score were calculated, one for the attenuated were calculated, one for the attenuated and full-blown psychotic positive sympand full-blown psychotic positive symptoms (ERI-PPS score) and one for the basic toms (ERI-PPS score) and one for the basic symptoms (ERI-BS). In addition, the posisymptoms (ERI-BS). In addition, the positive, negative and general psychopathology tive, negative and general psychopathology sub-scales of the Positive and Negative sub-scales of the Positive and Negative Syndrome Scale, (PANSS; Kay Syndrome Scale, (PANSS; Kay et al et al, 1987) , 1987) were used for assessment. Mood was aswere used for assessment. Mood was assessed by the Montgomery-Asberg Depressessed by the Montgomery-Å sberg Depression Rating Scale (MADRS; Montgomery sion Rating Scale (MADRS; Montgomery & Asberg, 1979) , and general level of func-& Asberg, 1979) , and general level of functioning by the Global Assessment of Functioning by the Global Assessment of Functioning scale, (GAF; American Psychiatric tioning scale, (GAF; American Psychiatric Association 1994). For safety evaluation, Association 1994). For safety evaluation, the Extrapyramidal Symptom Rating Scale the Extrapyramidal Symptom Rating Scale (ESRS; and (ESRS; and the UKU Side Effect Rating Scale (UKU; the UKU Side Effect Rating Scale (UKU; Lingjaerde Lingjaerde et al et al, 1987) were applied. Blood , 1987) were applied. Blood pressure and heart rate were measured on pressure and heart rate were measured on every visit, body mass index (BMI) was every visit, body mass index (BMI) was calculated every 4 weeks. Laboratory tests calculated every 4 weeks. Laboratory tests were performed at baseline, after 4 and 12 were performed at baseline, after 4 and 12 weeks, and every 3 months thereafter. weeks, and every 3 months thereafter.
Study design and intervention Study design and intervention
An open-label, randomised parallel-group An open-label, randomised parallel-group study was set up with an observation period study was set up with an observation period of up to 2 years. An open-label design was of up to 2 years. An open-label design was chosen to achieve best possible acceptance chosen to achieve best possible acceptance of the study at a time when pharmacoof the study at a time when pharmacological intervention in a pre-psychotic state logical intervention in a pre-psychotic state was a rather new idea. For recruitment, an was a rather new idea. For recruitment, an Inclusion Criteria Checklist was adapted Inclusion Criteria Checklist was adapted from the ERIraos, allowing an allocation from the ERIraos, allowing an allocation of participants to the EIPS, LIPS or GNRS of participants to the EIPS, LIPS or GNRS first episode of psychosis study. If a person first episode of psychosis study. If a person consented to participate, study-related consented to participate, study-related diagnostic measures (laboratory tests etc.) diagnostic measures (laboratory tests etc.) were performed and randomisation took were performed and randomisation took place locally at each centre. Baseline psyplace locally at each centre. Baseline psychopathology and safety measures were chopathology and safety measures were then assessed before the start of treatment. then assessed before the start of treatment. Both conditions featured a needs-focused Both conditions featured a needs-focused intervention, which, in the experimental intervention, which, in the experimental condition, was combined with the secondcondition, was combined with the secondgeneration antipsychotic amisulpride. generation antipsychotic amisulpride.
The needs-focused intervention went The needs-focused intervention went beyond usual clinical management because beyond usual clinical management because it could include psychoeducation, crisis it could include psychoeducation, crisis intervention, family counselling and assisintervention, family counselling and assistance with education or work-related diffitance with education or work-related difficulties, according to need. Regular culties, according to need. Regular psychotherapy was not provided. psychotherapy was not provided.
Amisulpride is a second-generation Amisulpride is a second-generation antipsychotic which has efficacy against antipsychotic which has efficacy against negative and affective symptoms, particunegative and affective symptoms, particularly in the low-dose range (Green, 2002 ; larly in the low-dose range (Green, 2002; Leucht Leucht et al et al, 2002) . In the current trial, , 2002). In the current trial, daily doses could range from 50 to 800 mg, daily doses could range from 50 to 800 mg, with increments of 50 mg at first step and with increments of 50 mg at first step and 100 mg at further steps. As a guideline, it 100 mg at further steps. As a guideline, it was suggested that the dosage be increased was suggested that the dosage be increased as long as attenuated or brief limited interas long as attenuated or brief limited intermittent positive symptoms were present. mittent positive symptoms were present.
The interval between such steps should be The interval between such steps should be at least 14 days if brief limited symptoms at least 14 days if brief limited symptoms were absent and the APS score had imwere absent and the APS score had improved. Participants visited the clinic proved. Participants visited the clinic weekly during the first 4 weeks, biweekly weekly during the first 4 weeks, biweekly until week 12 and monthly thereafter. until week 12 and monthly thereafter.
Use of chloral hydrate or short-acting Use of chloral hydrate or short-acting benzodiazepines (lorazepam, temazepam) benzodiazepines (lorazepam, temazepam) was allowed to treat agitation or sleep was allowed to treat agitation or sleep disturbances. Extrapyramidal symptoms disturbances. Extrapyramidal symptoms could be treated with biperiden. In line with could be treated with biperiden. In line with the Personal Assessment and Crisis Evaluathe Personal Assessment and Crisis Evaluation (PACE) study (McGorry tion (PACE) study (McGorry et al et al, 2002 (McGorry et al et al, ), , 2002 ), the use of antidepressants (citalopram) the use of antidepressants (citalopram) was permitted for moderate to severe was permitted for moderate to severe depression. depression.
Statistical analysis Statistical analysis
Acute symptomatic treatment effects as Acute symptomatic treatment effects as well as tolerability were analysed for the well as tolerability were analysed for the first 12 weeks of intervention. This period first 12 weeks of intervention. This period was the minimum for assessment of acute was the minimum for assessment of acute effects on negative and affective symptoms effects on negative and affective symptoms and global functioning (Moller and global functioning (Mö ller et al et al, , 1994; Smeraldi, 1998) . Randomised parti-1994; Smeraldi, 1998) . Randomised participants who completed the baseline assesscipants who completed the baseline assessment were considered eligible for ment were considered eligible for intention-to-treat (ITT) analyses. In case intention-to-treat (ITT) analyses. In case of premature drop-out, last-observation of premature drop-out, last-observation carried-forward analysis was used. As carried-forward analysis was used. As assumptions for repeated measurements assumptions for repeated measurements analysis of covariance (ANCOVA) were analysis of covariance (ANCOVA) were not always fulfilled, group comparisons not always fulfilled, group comparisons were performed by ANCOVA with the difwere performed by ANCOVA with the difference score (week 12 minus baseline) as ference score (week 12 . For between-group comparisons, (1988) . For between-group comparisons, effect size was calculated on the basis of effect size was calculated on the basis of residual values produced by ANCOVAs residual values produced by ANCOVAs including baseline and centre as terms including baseline and centre as terms . For safety evaluations of -test, Wilcoxon test) were used. Owing to marked differences in laboratory Owing to marked differences in laboratory methods for prolactin measurement, only methods for prolactin measurement, only relative indices such as percentage elevation relative indices such as percentage elevation from baseline to end-point could be considfrom baseline to end-point could be considered for analysis. ered for analysis.
Statistical significance was assumed Statistical significance was assumed at a two-tailed at a two-tailed a a4 40.05. Analyses were 0.05. Analyses were performed using SPSS for Windows version performed using SPSS for Windows version 12.02. 12.02. people who consented to participate' 65 people who consented to participate' 65 were randomised to amisulpride plus were randomised to amisulpride plus needs-focused intervention and 59 to the needs-focused intervention and 59 to the control group (Fig. 1) . Eighteen people control group (Fig. 1) . Eighteen people dropped out before the baseline assessdropped out before the baseline assessments (4 in the group with amisulpride ments (4 in the group with amisulpride and 14 in the control group ( and 14 in the control group (w w 2 2 ¼8.9, 8.9, s 8 9 s 8 9 d.f. d.f.¼1, 1, P P5 50.01). The remaining 106 were 0.01). The remaining 106 were considered for the safety analysis. Three considered for the safety analysis. Three participants in the group with amisulpride participants in the group with amisulpride had to be excluded from the analysis of had to be excluded from the analysis of acute effect as treatment had already acute effect as treatment had already started before baseline assessment. Another started before baseline assessment. Another participant in the group with needs-focused participant in the group with needs-focused intervention had a severe, unstable endointervention had a severe, unstable endocrinological dysfunction which was not crinological dysfunction which was not detectable by routine laboratory measuredetectable by routine laboratory measurement. Hence, 102 patients (58 in the amiment. Hence, 102 patients (58 in the amisulpride group and 44 controls) were sulpride group and 44 controls) were eligible for statistical analysis (ITT sample). eligible for statistical analysis (ITT sample).
RESULTS RESULTS

Sample Sample
Baseline characteristics Baseline characteristics
Age, gender and distribution of inclusion Age, gender and distribution of inclusion criteria were not statistically different criteria were not statistically different between groups (Table 1) . Early drop-outs between groups (Table 1) . Early drop-outs ( (n n¼18) did not differ from the remaining 18) did not differ from the remaining sample ( sample (n n¼106) with respect to any of these 106) with respect to any of these variables. This also applied when comparivariables. This also applied when comparisons were made separately for the two sons were made separately for the two treatment groups. Regarding baseline treatment groups. Regarding baseline psychopathology of the ITT sample ( 
Dosage and concomitant Dosage and concomitant medication medication
The mean daily dose of amisulpride was The mean daily dose of amisulpride was 118.7 mg (s.e. 118.7 mg (s.e.¼10.7, median 98.1), the 10.7, median 98.1), the mean maximum dose 181.9 mg (s.e. mean maximum dose 181.9 mg (s.e.¼19.0, 19.0, median 137.5) and the mean dose at endmedian 137.5) and the mean dose at endpoint 169.5 mg (s.e. point 169.5 mg (s.e.¼18.5, median 18.5, median 100.0 mg). Additional selective serotonin 100.0 mg). Additional selective serotonin reuptake inhibitors (SSRIs) were prescribed reuptake inhibitors (SSRIs) were prescribed in seven participants in each group (NS). In in seven participants in each group (NS). In three of seven from the amisulpride group three of seven from the amisulpride group pre-study medication was continued. pre-study medication was continued. Benzodiazepines were prescribed for six Benzodiazepines were prescribed for six participants: five in the amisulpride group, participants: five in the amisulpride group, with one starting before study entry, and with one starting before study entry, and one in the control group (NS). One partione in the control group (NS). One participant in each group took chloral hydrate cipant in each group took chloral hydrate to prevent sleep disturbances. to prevent sleep disturbances.
Psychopathological outcome Psychopathological outcome measures measures
The combined treatment produced a signifThe combined treatment produced a significantly superior effect on ERI-BAPPSS icantly superior effect on ERI-BAPPSS scores ( scores (F F (1,98) ( Table 2 provides the pre-and 0.01). Table 2 provides the pre-and post-treatment scores and Fig. 2 the effect post-treatment scores and Fig. 2 the effect sizes for between-and within-group comsizes for between-and within-group comparisons. Amisulpride produced a large parisons. Amisulpride produced a large effect, whereas needs-focused intervention effect, whereas needs-focused intervention alone produced only a small effect on alone produced only a small effect on ERI-BAPPSS scores. The same pattern ERI-BAPPSS scores. The same pattern applied for ERI-PPS scores ( applied for ERI-PPS scores (F F (1,98) ( A significant effect of treatment with A significant effect of treatment with amisulpride also emerged regarding the amisulpride also emerged regarding the PANSS positive sub-scale (PANSS-P) score PANSS positive sub-scale (PANSS-P) score ( (F F (1,98) (1,98)¼7.83, 7.83, P P5 50.01); paired 0.01); paired t t-tests -tests revealed a significant decrease of baseline revealed a significant decrease of baseline scores only in the group with amisulpride scores only in the group with amisulpride ( (t t¼5.50, d.f.
5.50, d.f.¼57, 57, P P5 50.001). Across sam-0.001). Across samples, baseline and difference scores of ERIples, baseline and difference scores of ERI-PSS and PANSS-P showed a significant but PSS and PANSS-P showed a significant but moderate correlation ( moderate correlation (r r¼0.34, 0.34, P P5 50.001 0.001 and and r r¼0.39, 0.39, P P5 50.001 respectively). 0.001 respectively). Analysis of PANSS negative sub-scale Analysis of PANSS negative sub-scale (PANSS-N) scores by ANCOVA also (PANSS-N) scores by ANCOVA also yielded a significantly better effect of yielded a significantly better effect of s 9 0 s 9 0 AUTHOR'S PROOF AUTHOR'S PROOF Fig. 3 ). 0.01; Fig. 3 ).
Safety Safety
The only severe adverse event occurred in The only severe adverse event occurred in the group with needs-focused intervention the group with needs-focused intervention alone where, despite starting treatment alone where, despite starting treatment with citalopram, a patient became severely with citalopram, a patient became severely depressed and suicidal. The numbers and depressed and suicidal. The numbers and reasons for drop-outs are given in Fig. 1 . reasons for drop-outs are given in Fig. 1 . 556.9%; NS), a pattern repeated when males and females were repeated when males and females were analysed separately. Significant clinical analysed separately. Significant clinical side-effects associated with increased proside-effects associated with increased prolactin levels are listed in Table 3 . Menstrual lactin levels are listed in Table 3 . Menstrual disturbances emerged only transiently in disturbances emerged only transiently in four females; another female developed a four females; another female developed a prolonged cycle and another dropped out prolonged cycle and another dropped out later owing to amenorrhoea. Among males, later owing to amenorrhoea. Among males, two developed erectile and ejaculatory two developed erectile and ejaculatory dysfunction and another decreased sexual dysfunction and another decreased sexual desire and erectile dysfunction. desire and erectile dysfunction.
Liver alanine aminotransferase levels Liver alanine aminotransferase levels more than twice the upper limit of normal more than twice the upper limit of normal were reported in three participants in the were reported in three participants in the amisulpride group (4.9%). amisulpride group (4.9%). Extrapyramidal symptoms were anaExtrapyramidal symptoms were analysed with respect to the ESRS total score lysed with respect to the ESRS total score (range 0-225) and for the sub-scales (range 0-225) and for the sub-scales 'parkinsonism' (range 0-96), 'akathisia' 'parkinsonism' (range 0-96), 'akathisia' (range 0-9), 'dyskinesia' (range 0-42) and (range 0-9), 'dyskinesia' (range 0-42) and 'dystonia' (range 0-60) according to 'dystonia' (range 0-60) according to . WithinChouinard & Margolese (2005) . Withingroup comparisons revealed no statistically group comparisons revealed no statistically significant change from baseline to endsignificant change from baseline to endpoint in either group. At end-point, total point in either group. At end-point, total scores ranged from 0 to 5 in the control scores ranged from 0 to 5 in the control group and from 0 to 19 in the amisulpride group and from 0 to 19 in the amisulpride group, with 36 of 61 (59.0%) in the amisulgroup, with 36 of 61 (59.0%) in the amisulpride group showing no symptoms and 21 pride group showing no symptoms and 21 of 61 (34.4%) exhibiting scores from 1 to of 61 (34.4%) exhibiting scores from 1 to 5. No statistically significant differences 5. No statistically significant differences emerged between groups with regard to emerged between groups with regard to change in scores (baseline change in scores (baseline v.
v. end-point) or end-point) or scores at end-point, except for the akathisia scores at end-point, except for the akathisia end-point scores (amisulpride mean 0.5, end-point scores (amisulpride mean 0. and control groups respectively amisulpride and control groups respectively crossed the threshold for 'presence of crossed the threshold for 'presence of akathisia' (score akathisia' (score5 53). Biperiden was pre-3). Biperiden was prescribed for 3 of 51 amisulpride-treated parscribed for 3 of 51 amisulpride-treated participants. The daily mean, maximum and ticipants. The daily mean, maximum and end-point doses of amisulpride in these parend-point doses of amisulpride in these participants were 239.4, 408.3, and 333.3 mg ticipants were 239.4, 408.3, and 333.3 mg respectively. respectively.
The BMI increased slightly but signifiThe BMI increased slightly but significantly in the amisulpride group (mean cantly in the amisulpride group (mean end-point minus baseline end-point minus baseline¼0.63 (2.6%), 0.63 (2.6%), s.e. s.e.¼0.14, 0.14, Z Z¼7 73.71, 3.71, P P5 50.001); mean 0.001); mean group changes differed significantly group changes differed significantly ( (U U¼389.0, 389.0, P P¼0.001). Diastolic blood pres-0.001). Diastolic blood pressure increased slightly but significantly in sure increased slightly but significantly in the group with needs-focused intervention the group with needs-focused intervention alone (+3.49 mmHg, s.e. alone (+3.49 mmHg, s.e.¼1.64, 1.64, Z Z¼2.12, 2.12, P P5 50.05) but no significant group differ-0.05) but no significant group difference emerged. Systolic blood pressure or ence emerged. Systolic blood pressure or heart rate in the sedentary position did heart rate in the sedentary position did not change significantly in either group; not change significantly in either group; ECG recordings revealed no pathological ECG recordings revealed no pathological changes. changes.
DISCUSSION DISCUSSION
The early intervention studies of the GNRS The early intervention studies of the GNRS follow a unique two-phase approach, diffollow a unique two-phase approach, differentiating between an early and a late ferentiating between an early and a late initial prodromal state (Hafner initial prodromal state (Hä fner et ) and/ or a combination of functional decline or a combination of functional decline and trait risk factors, whereas the latter and trait risk factors, whereas the latter comprises emergence of attenuated and/or comprises emergence of attenuated and/or brief limited intermittent positive sympbrief limited intermittent positive symptoms. This approach has the theoretical toms. This approach has the theoretical potential to detect the prodrome of psychopotential to detect the prodrome of psychosis well in advance of the start of functional sis well in advance of the start of functional decline (i.e. 2-4 years before first admission decline (i.e. 2-4 years before first admission for overt psychosis; Hafner for overt psychosis; Hä fner et al et al, 1998), , 1998), and thus much earlier than with imminent and thus much earlier than with imminent or ultra-high-risk criteria (Phillips or ultra-high-risk criteria (Phillips et al et al, , 2000; Woods 2000; Woods et al et al, 2003) . Corresponding , 2003) . Corresponding to the two-phase model, a two-step treatto the two-phase model, a two-step treatment approach was developed, offering ment approach was developed, offering cognitive-behavioural therapy (CBT) for cognitive-behavioural therapy (CBT) for patients putatively in the early state and patients putatively in the early state and antipsychotic treatment for those already antipsychotic treatment for those already in the late state. The definition of LIPS in the late state. The definition of LIPS corresponds to the PACE criteria (Phillips corresponds to the PACE criteria (Phillips et al et al, 2000) , with the major difference that , 2000), with the major difference that entry criteria for the LIPS study are entry criteria for the LIPS study are restricted to symptoms of the positive restricted to symptoms of the positive psychotic spectrum. Thus in the search for psychotic spectrum. Thus in the search for a pharmacological treatment option the a pharmacological treatment option the investigation of an antipsychotic drug was investigation of an antipsychotic drug was consistent with the clinical symptoms. Amiconsistent with the clinical symptoms. Amisulpride was primarily chosen because sulpride was primarily chosen because safety data in studies of schizophrenia indisafety data in studies of schizophrenia indicated a favourable tolerability profile especated a favourable tolerability profile especially in the low-dose range. The incidence cially in the low-dose range. The incidence of extrapyramidal side-effects has been of extrapyramidal side-effects has been s 9 2 s 9 2 AUTHOR'S PROOF AUTHOR'S PROOF . ERI, 0.80: 'large' . ERI, Early Recognition Inventory; BAPPSS, Basic and Positive Psychosis Spectrum Symptoms; PPS, Positive Psychosis Early Recognition Inventory; BAPPSS, Basic and Positive Psychosis Spectrum Symptoms; PPS, Positive Psychosis Spectrum; BS, Basic Symptoms; PANSS, Positive and Negative Syndrome Scale; P, positive symptoms; Spectrum; BS, Basic Symptoms; PANSS, Positive and Negative Syndrome Scale; P, positive symptoms; N, negative symptoms; G, general psychopathology; MADRS, Montgomery^-sberg Depression Rating Scale; N, negative symptoms; G, general psychopathology; MADRS, Montgomery^-sberg Depression Rating Scale;
GAF, Global Assessment of Functioning scale. GAF, Global Assessment of Functioning scale. reported to be similar to placebo in a dose reported to be similar to placebo in a dose range between 50 and 300 mg, that exrange between 50 and 300 mg, that expected to be prescribed throughout the pected to be prescribed throughout the study (Leucht study (Leucht et al et al, 2002) . Furthermore, , 2002) . Furthermore, weight gain is small (Leucht weight gain is small (Leucht et al et al, 2004) . , 2004). Moreover, amisulpride has a unique effiMoreover, amisulpride has a unique efficacy for positive, negative and depressive cacy for positive, negative and depressive symptoms (Green, 2002; symptoms (Green, 2002; Leucht Leucht et al et al, , 2002) and was thus assumed to be particu-2002) and was thus assumed to be particularly suitable for the prodromal larly suitable for the prodromal phase 
Main findings Main findings
In the present study, across all measures In the present study, across all measures amisulpride in combination with needsamisulpride in combination with needsfocused intervention intervention produced focused intervention intervention produced superior treatment effects compared with superior treatment effects compared with needs-focused intervention alone. The needs-focused intervention alone. The strongest effects were observed for attenustrongest effects were observed for attenuated and brief limited intermittent positive ated and brief limited intermittent positive symptoms. As they are assumed to be the symptoms. As they are assumed to be the most important indicators of imminent most important indicators of imminent risk, it is noteworthy that a complete rerisk, it is noteworthy that a complete regression of scores appeared more than gression of scores appeared more than twice as often in the amisulpride group. twice as often in the amisulpride group. Another strong effect emerged for basic Another strong effect emerged for basic symptoms, which are also closely assosymptoms, which are also closely associated with an enhanced risk for psychosis ciated with an enhanced risk for psychosis (Klosterkotter (Klosterkö tter et al et al, 2001) . The future , 2001). The future long-term course of the study will have to long-term course of the study will have to show whether disappearance of psychoshow whether disappearance of psychopathological risk indicators is associated pathological risk indicators is associated with lower rates of transition to psychosis. with lower rates of transition to psychosis.
Since the GNRS model of the proSince the GNRS model of the prodromal phase called for an instrument indromal phase called for an instrument integrating both basic symptoms and the tegrating both basic symptoms and the ultra-high-risk approach, the ERIraos was ultra-high-risk approach, the ERIraos was used for the assessment of course. The used for the assessment of course. The PANSS does not sufficiently assess positive PANSS does not sufficiently assess positive symptoms below the psychotic threshold symptoms below the psychotic threshold but was employed in this study as it is but was employed in this study as it is widely used in antipsychotic trials and prowidely used in antipsychotic trials and provides an established evaluation of negative vides an established evaluation of negative symptoms. symptoms.
Recent findings indicate that low GAF Recent findings indicate that low GAF scores are associated with an increased risk scores are associated with an increased risk for psychosis, especially in combination for psychosis, especially in combination with attenuated or brief limited interwith attenuated or brief limited intermittent positive symptoms (Yung mittent positive symptoms (Yung et al et al, , 2006) . Hence, the improvement of GAF 2006). Hence, the improvement of GAF scores in the amisulpride group might also scores in the amisulpride group might also be predictive for a diminished risk. Howbe predictive for a diminished risk. However, as the GAF score does not merely asever, as the GAF score does not merely assess the level of functioning but integrates sess the level of functioning but integrates the occurrence and severity of symptoms, the occurrence and severity of symptoms, in future studies a more specific instrument in future studies a more specific instrument such as the Social and Occupational such as the Social and Occupational Functioning Assessment Scale (SOFAS; Functioning Assessment Scale (SOFAS; Goldman Goldman et al et al, 1992 ) might help to further , 1992) might help to further clarify the effect of treatment on functionclarify the effect of treatment on functioning and its value as a risk indicator. ing and its value as a risk indicator.
Negative symptoms have recently been Negative symptoms have recently been defined as a separate target of antipsychotic defined as a separate target of antipsychotic treatment as they are particularly important treatment as they are particularly important to functional outcome and quality of life to functional outcome and quality of life (Kirkpatrick (Kirkpatrick et al et al, 2006) . The use of , 2006) . The use of amisulpride resulted in an improvement in amisulpride resulted in an improvement in negative symptoms which was not observed negative symptoms which was not observed with needs-focused intervention alone. with needs-focused intervention alone.
The 3-month study period was obviously The 3-month study period was obviously sufficient to detect differential effects of sufficient to detect differential effects of treatment on global functioning, affective treatment on global functioning, affective and negative symptoms, but recent studies and negative symptoms, but recent studies suggest that long-term data will show further suggest that long-term data will show further improvements (Laughren & Levin, 2006) . improvements (Laughren & Levin, 2006) .
Depressive symptoms improved in both Depressive symptoms improved in both groups, again with an advantage for the groups, again with an advantage for the amisulpride group. Concomitant SSRIs amisulpride group. Concomitant SSRIs were prescribed only for a few participants, were prescribed only for a few participants, with numbers nearly equal in both groups. with numbers nearly equal in both groups. However, a confounding effect on the However, a confounding effect on the results cannot be ruled out. results cannot be ruled out.
Mean doses of amisulpride were in the Mean doses of amisulpride were in the expected low dose range, yet it can be asexpected low dose range, yet it can be assumed that the treatment effects especially sumed that the treatment effects especially on the psychosis spectrum symptoms could on the psychosis spectrum symptoms could have been further increased with somewhat have been further increased with somewhat higher doses. However, the low mean higher doses. However, the low mean dosage may also have been responsible for dosage may also have been responsible for the good overall tolerability, as demonthe good overall tolerability, as demonstrated by the low rate of drop-outs related strated by the low rate of drop-outs related to adverse events. In line with the literature to adverse events. In line with the literature (Leucht (Leucht et al et al, 2002 (Leucht et al et al, , 2004 (Leucht et al et al, ), amisulpride , 2002 (Leucht et al et al, , 2004 , amisulpride showed a most favourable side-effect proshowed a most favourable side-effect profile in terms of extrapyramidal symptoms file in terms of extrapyramidal symptoms and weight gain, and did not influence and weight gain, and did not influence blood pressure or heart rate. As a special blood pressure or heart rate. As a special feature of benzamides, amisulpride markedly feature of benzamides, amisulpride markedly increased prolactin levels. In line with increased prolactin levels. In line with recent findings, this effect was not doserecent findings, this effect was not doserelated but was enhanced when SSRIs were related but was enhanced when SSRIs were combined (Bressan combined (Bressan et al et al, 2004; Kopecek , 2004; Kopecek et et al al, 2004) . In some patients a rise in prolac-, 2004) . In some patients a rise in prolactin levels was associated with side-effects tin levels was associated with side-effects such as galactorrhoea or mostly transient such as galactorrhoea or mostly transient menstrual disorders. However, the related menstrual disorders. However, the related number of drop-outs was fairly low. A temnumber of drop-outs was fairly low. A temporary decrease in libido occurred in almost porary decrease in libido occurred in almost all patients. Its origin is often difficult to all patients. Its origin is often difficult to disentangle, as current mental state itself disentangle, as current mental state itself s 9 3 s 9 3 AUTHOR'S PROOF AUTHOR'S PROOF Table 3  Table 3 Adverse events (UKU side-effects scale) with a severity of at least moderate and a frequency of at Adverse events (UKU side-effects scale) with a severity of at least moderate and a frequency of at least 5% least 5% Other studies Other studies
To our knowledge, only one other conTo our knowledge, only one other controlled study on the short-term symptotrolled study on the short-term symptomatic effects in the putatively prodromal matic effects in the putatively prodromal state has been published to date. The state has been published to date. The Prevention through Risk Identification, Prevention through Risk Identification, Management and Education (PRIME) Management and Education (PRIME) study compared olanzapine ( study compared olanzapine (n n¼30) and 30) and placebo ( placebo (n n¼29) over 8 weeks (Woods 29) over 8 weeks (Woods et et al al, 2003) . In addition, psychosocial inter-, 2003) . In addition, psychosocial intervention with supportive and psychoeduvention with supportive and psychoeducational components was offered to both cational components was offered to both groups, which seems to correspond to the groups, which seems to correspond to the needs-focused intervention control condineeds-focused intervention control condition in the present trial. In a mixed-model tion in the present trial. In a mixed-model analysis, olanzapine significantly improved analysis, olanzapine significantly improved total, negative, disorganised and positive total, negative, disorganised and positive scores on the SOPS. The effect on the scores on the SOPS. The effect on the positive scores, however, was not statispositive scores, however, was not statistically different from placebo and general tically different from placebo and general scores did not significantly change with scores did not significantly change with either treatment. The PANSS positive and either treatment. The PANSS positive and general psychopathology scores changed general psychopathology scores changed significantly in both groups, but no effect significantly in both groups, but no effect was observed with negative symptoms, was observed with negative symptoms, MADRS or GAF scores. Compared with MADRS or GAF scores. Compared with the present study, the PRIME study has the present study, the PRIME study has the clear the clear advantage of a double-blind, advantage of a double-blind, placeboplacebo-controlled design. However, owing controlled design. However, owing to its smaller sample sizes, the study may to its smaller sample sizes, the study may have been underpowered as in the lasthave been underpowered as in the lastobservation-carried-forward analysis no observation-carried-forward analysis no group difference became statistically signifgroup difference became statistically significant despite the fact that, for example, the icant despite the fact that, for example, the mean SOPS positive score improved about mean SOPS positive score improved about 4.5 times more with olanzapine. 4.5 times more with olanzapine.
The only other published controlled The only other published controlled early intervention study which includes an early intervention study which includes an antipsychotic is the PACE study (McGorry antipsychotic is the PACE study (McGorry et al et al, 2002) . In an open-label design, a com-, 2002) . In an open-label design, a combination of needs-based intervention, CBT bination of needs-based intervention, CBT and risperidone was tested against an excluand risperidone was tested against an exclusive needs-based intervention. However, sive needs-based intervention. However, comparability with the present study is comparability with the present study is limited, as transition rate to psychosis was limited, as transition rate to psychosis was the main outcome measure of the PACE the main outcome measure of the PACE study, and symptomatic effects were thus study, and symptomatic effects were thus only reassessed after 6 months. Despite a only reassessed after 6 months. Despite a clearly superior effect of the combination clearly superior effect of the combination on transition rates, symptomatic improveon transition rates, symptomatic improvement was not different between groups, ment was not different between groups, which may in part have been because of which may in part have been because of adherence in the risperidone group. adherence in the risperidone group.
Limitations Limitations
A limitation of the current study is the lack A limitation of the current study is the lack of masking, which it shares with the PACE of masking, which it shares with the PACE study and which may have led to an overstudy and which may have led to an overestimation of effects owing to rater bias estimation of effects owing to rater bias and/or placebo effects. It seems unlikely, and/or placebo effects. It seems unlikely, however, that a placebo effect would have however, that a placebo effect would have produced such marked differences in effect produced such marked differences in effect size after 12 weeks of treatment. The results size after 12 weeks of treatment. The results are supported by the PRIME study, in are supported by the PRIME study, in which PANSS positive scores decreased by which PANSS positive scores decreased by only 1.6% in the placebo group but by only 1.6% in the placebo group but by 15.3% in the olanzapine group. Thus the 15.3% in the olanzapine group. Thus the placebo effect might be rather weak in this placebo effect might be rather weak in this group of patients. However, the current group of patients. However, the current results justify a placebo-controlled, results justify a placebo-controlled, double-blind trial. double-blind trial.
Another limitation is that the needsAnother limitation is that the needsfocused intervention had some effects on focused intervention had some effects on positive psychotic spectrum and basic positive psychotic spectrum and basic symptoms. Hence, as in the PACE study symptoms. Hence, as in the PACE study and presumably the PRIME study, it is and presumably the PRIME study, it is not possible to disentangle the effects of not possible to disentangle the effects of drug and psychosocial support. However, drug and psychosocial support. However, improvement of global functioning and improvement of global functioning and most notably negative symptoms might be most notably negative symptoms might be predominantly attributable to amisulpride, predominantly attributable to amisulpride, as the needs-focused intervention alone as the needs-focused intervention alone had no effect on this measure. had no effect on this measure.
Another limitation is the number of Another limitation is the number of early drop-outs in the control group. As early drop-outs in the control group. As the participants did not return, the reasons the participants did not return, the reasons for drop-out are unknown in most cases. for drop-out are unknown in most cases. The significant difference in drop-outs The significant difference in drop-outs between the two conditions might indicate between the two conditions might indicate that psychosocial support alone did not that psychosocial support alone did not meet the subjective needs of at least some meet the subjective needs of at least some participants, but that a combined treatment participants, but that a combined treatment was more acceptable. was more acceptable.
Conclusions Conclusions
The present trial suggests that an antiThe present trial suggests that an antipsychotic drug treatment provides a psychotic drug treatment provides a marked symptomatic benefit for people in marked symptomatic benefit for people in a putatively late initial prodromal state. a putatively late initial prodromal state. Confirmation of the results in a placeboConfirmation of the results in a placebocontrolled study would be an obligatory controlled study would be an obligatory prerequisite for any general recommendaprerequisite for any general recommendations. Amisulpride was well tolerated in tions. Amisulpride was well tolerated in terms of extrapyramidal symptoms and terms of extrapyramidal symptoms and weight gain. Although prolactin levels were weight gain. Although prolactin levels were increased more frequently with amisulincreased more frequently with amisulpride, only a small number of participants pride, only a small number of participants developed clinical symptoms. However, in developed clinical symptoms. However, in the search for effective acute treatments the search for effective acute treatments for prodromal symptoms it seems only reafor prodromal symptoms it seems only reasonable to expect that as in the treatment of sonable to expect that as in the treatment of overt psychosis no antipsychotic suits all overt psychosis no antipsychotic suits all patients. With regard to the ethics of prepatients. With regard to the ethics of preventive early intervention (McGlashan, ventive early intervention (McGlashan, 2005) , our results suggest that patients in 2005), our results suggest that patients in a putatively prodromal state seeking help a putatively prodromal state seeking help for their symptoms experience a substantial for their symptoms experience a substantial benefit from treatment, independent of benefit from treatment, independent of their further course. However, in the light their further course. However, in the light of the emerging findings about the marked of the emerging findings about the marked disabilities already present in the late disabilities already present in the late prodromal or ultra-high-risk state, it might prodromal or ultra-high-risk state, it might be helpful to complement the criteria for be helpful to complement the criteria for attenuated and brief limited intermittent attenuated and brief limited intermittent positive symptoms with a functional positive symptoms with a functional dimen dimension, thus making it clear that early sion, thus making it clear that early intervention does not only treat single psyintervention does not only treat single psychopathological symptoms or assumed risks chopathological symptoms or assumed risks in otherwise healthy people but suffering in otherwise healthy people but suffering human beings. human beings.
